Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules
Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook
Männedorf, Switzerland, October 13, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today provided a qualitative update on its performance for the third quarter of 2025.
Sales for the third quarter increased by a mid-single-digit percentage in local currencies, representing a further sequential improvement after a mid-single-digit decline in Q1 and a low-single-digit decline in Q2. At the segment level, the Life Sciences Business recorded a low-single-digit sales decline and the Partnering Business achieved a sales increase in the low teens percentage range, both in local currencies and in line with expectations. For both segments, order intake exceeded sales in the third quarter, and the book-to-bill ratio remained above 1.
Outlook for full-year 2025 confirmed
While the key assumptions underlying the full-year 2025 sales outlook remain largely consistent with those communicated on March 12, 2025, Tecan provides the following update:
-
For US Academia & Government, sales are trending toward the middle of the initially assumed range (communicated range: from halving of 2024 revenues to a decline in the teens).
-
In China, demand stays subdued and sales are tracking slightly below the lower end of the initially assumed range (communicated range: high single-digit percentage decline to stable sales).
-
Biopharma sales in the second half are expected to remain broadly in line with the stable sales development seen in the first half (communicated range: no meaningful improvement in H2 to a more significant improvement).
-
Newly launched products and growth segments continue to make a solid contribution.
-
Sales to the largest Partnering Business customer are expected to be at the upper end of the initial range, i.e., stable compared to the prior year (communicated range: moderate decrease in sales to stable sales development).
-
In the Synergence part of the Partnering Business, some customers have indicated they may postpone orders in the fourth quarter, anticipating Tecan’s tariff mitigation measures – expected to be implemented by Q1 2026 – to reduce the tariff burden for these OEM customers.
Based on these trends and nine months of actual results, Tecan confirms its full-year sales outlook, expecting sales in local currencies to be within the previously communicated range – from a low single-digit percentage decline to low single-digit percentage growth, with current trends indicating that full-year performance will be in the lower half of the range.
